Transparency in Compliance and Enforcement Data Proposals Comments

CPC’s comments to FDA recommending that FDA’s Transparency Initiative encompass combination products and recommending how combination product issues can be incorporated into the FDA’s Draft Proposals for Public Comment to Increase Transparency by Promoting Greater Access to the Agency’s Compliance and Enforcement Data.